GRPH - Graphite Bio: Assessing Prospects Amid Doubts Raised On Safety Of Crispr
- Graphite Bio is a clinical-stage development biotech making use of CRISPR-based gene-editing therapy to develop a cure for sickle cell disease.
- Now, a biotechnology journal has published an adverse report on the safety of CRISPR-Cas9.
- As a result, the shares dipped, but have recovered partly.
- I make sense of the implications by going deeper into the report and, based on my assessment, the biotech's therapy has a differentiated gene correction approach.
- Operating in a highly specialized medical field and combating a life-threatening disease, the company is a buy at current prices, but the road towards commercialization will be a long and tortuous one.
For further details see:
Graphite Bio: Assessing Prospects Amid Doubts Raised On Safety Of Crispr